Endo International

Endo International Plc operates as a pharmaceutical company, which engages in the development, manufacture, and distribution of branded and generic pharmaceutical products. It operates through the following segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. The Branded Pharmaceuticals segment conducts certain operations in the U.S. through leased and owned manufacturing properties in Pennsylvania, New York and New Jersey, as well as certain administrative and R&D functions through leased properties in Pennsylvania. The Sterile Injectables segment includes manufacturing, quality assurance, research and development, and administration functions. The Generic Pharmaceuticals segment is composed of manufacturing, distribution, quality assurance and administration functions, as well as certain research and development functions. The International Pharmaceuticals segment’s operations are currently conducted through Paladin’s leased headquarters in Montreal, Canada. The company was founded in 1997 and is headquartered Dublin, Ireland.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Endo Health Solutions Inc. provides specialty healthcare solutions in the United States and internationally. The company’s Endo Pharmaceuticals segment offers branded prescription products,.

DUBLIN , July 1, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced top-line results from its Phase 2 study of Collagenase Clostridium Histolyticum (or "CCH") in participants with adhesive capsulitis (AC) of the shoulder, commonly known as "frozen shoulder." While Phase 2 study participants receiving up to three doses of CCH showed some improvement in the change from baseline in the adapted American Shoulder and Elbow Surgeons (ASES) Standardized Shoulder Form composite score for the affected shoulder at the Day 95 visit, the difference compared to those study participants receiving placebo was not statistically significant.

Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants with Adhesive Capsulitis of the Shoulder

Here's what investors may want to know about today's 20% downside move in ENDO stock, a day after this stock rocketed 90% higher. The post Endo International (ENDP) Stock Plunges 20% After Missing Interest Payment appeared first on InvestorPlace.

Endo International (ENDP) Stock Plunges 20% After Missing Interest Payment

Endo International (ENDO) tanks 26%, cooling off after its massive stock price surge on Tuesday, post the Supreme Court's decision to overturn Roe v. Wade.

Why Endo (ENDP) Stock Wilted After its Surge on Tuesday?

APA Corporation

Chevron

Devon Energy

Enphase Energy

JinkoSolar Holding

Lytus Technologies Holdings PTV Ltd

NextEra Energy

Shoals Technologies Group

Exxon Mobil

Investing in energy can be a key part of your portfolio. This guide will help you invest in oil, natural gas and renewable energy stocks.

Energy Stocks: An Investment Guide

Amazon

Shopify

At the end of the day, stock splits are a matter of simple arithmetic. Here's a closer look at what you should know about stock splits.

What Is a Stock Split and How Does It Work?

Endo International has been surging all day but it isn't just Plan B that has kept it rising. Here's why ENDP stock is a name to watch.

Why Is Endo International (ENDP) Stock Up 90% Today?

Wejo Group Ltd

Bird Rides

JanOne Inc

Tuniu Corp

Penny stocks to watch with news The post Penny Stocks To Watch: Why TOUR, JAN, ENDP, BRDS & WEJO Stock Are Moving appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Watch: Why TOUR, JAN, ENDP, BRDS & WEJO Stock Are Moving

Clovis Oncology

VBI Vaccines

Check these three biotech penny stocks out for your watchlist right now The post 3 Biotech Penny Stocks That Climbed in After-Hours Trading appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Biotech Penny Stocks That Climbed in After-Hours Trading

Revlon

Uranium Energy

Here's what you need to know about trading penny stocks on June 15th The post What to Know About Buying Penny Stocks on June 15th  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Know About Buying Penny Stocks on June 15th

Endo (ENDP) collaborates with Taiwan Liposome to commercialize TLC599, an extended and controlled release liposomal formulated dexamethasone for chronic knee osteoarthritis (OA) pain.

Endo (ENDP) Inks Deal for Osteoarthritis Knee Pain Drug

Kaival Brands Innovations Group

Here's what you need to know about trading penny stocks on June 14th The post What to Know About Trading Penny Stocks on June 14th  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Know About Trading Penny Stocks on June 14th

DUBLIN , June 13, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited (EVL) has executed an agreement with Taiwan Liposome Company, Ltd. (TLC), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, to commercialize TLC599, a TLC investigational product.

Endo Executes Agreement With TLC to Commercialize Phase 3 Orthopedic Product for the Treatment of Osteoarthritis Knee Pain

Camber Energy

Imperial Petroleum

Can these penny stocks climb this coming month? The post Penny Stocks to Add to Your Watchlist Next Week, 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks to Add to Your Watchlist Next Week, 3 to Watch

FuelCell Energy

Geovax Labs

Here are three penny stocks to watch after today's bullish session The post Top Penny Stocks to Watch After a Bullish Trading Day  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks to Watch After a Bullish Trading Day

Endo (ENDP) plunges on reports of negotiations with its lenders and senior bondholders about a possible restructuring of more than $8 billion of debt.

Endo (ENDP) Crashes 46.54% as it Looks to Restructure Debt

Reports that the specialty pharmaceutical company is looking to restructure debt prompted the drop.

Why Shares of Endo International Plummeted 69% on Wednesday

Endo International Plc (NASDAQ: ENDP) initiated negotiations with its lenders and senior bondholders regarding a possible reorganization of more than $8 billion of its debt, the Wall Street Journal reported, citing people familiar with the matter. Lenders began talks after the.

What Is Happening With Endo Shares Today

NEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc. (together with certain of its affiliates and clients, “BHG” or “we”), the New York City-based investment advisor to clients with financial interests in Endo International Plc. (“Endo” or the “Company”) (NASDAQ: ENDP), today issued an open letter to shareholders and creditors of the Company, relating to corporate malfeasance and false statements of financial position. The full open letter to the Company's shareholders and creditors, alon

Buxton Helmsley Issues Letter to Endo International Plc. Shareholders and Creditors, Relating to Corporate Malfeasance and False Statements of Financials

Endo (ENDP) tops Q1 earnings and sales estimates. However, Vasostrict faces generic competition and the guidance for Q2 is dismal.

Endo (ENDP) Beats on Q1 Earnings, Guides Weak Q2 Results

Endo International plc's (NASDAQ: ENDP) Q1 sales decreased 9% to $652.26 million, beating the consensus of $633.41 million. The decrease was attributable to decreased revenues from the sterile injectables segment, partially offset by increased revenues from the generic segment and.

Endo Shares Plummet On Decreasing Sales, Wider Loss; Outlook Lagging Consensus

The company provided disappointing Q2 guidance.

Why Endo International Stock Is Cratering Today

Endo International plc (NASDAQ:ENDP ) Q1 2022 Earnings Conference Call May 6, 2022 7:30 AM ET Company Participants Laure Park - Senior Vice President, Investor Relations and Corporate Affairs Blaise Coleman - President and Chief Executive Officer Mark Bradley - Executive right Vice President and Chief Financial Officer Patrick Barry - President, Global Commercial Operations Conference Call Participants Chris Schott - JPMorgan David Amsellem - Piper Sandler Gary Nachman - BMO Capital Markets Nathan Rich - Goldman Sachs Operator Good day and welcome to the First Quarter 2022 Endo International Plc Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded.

Endo International plc (ENDP) CEO Blaise Coleman on Q1 2022 Results - Earnings Call Transcript

Endo (ENDP) delivered earnings and revenue surprises of 50% and 1.73%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Endo International (ENDP) Surpasses Q1 Earnings and Revenue Estimates

DUBLIN , May 5, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today reported financial results for the first-quarter ended March 31, 2022 and provided second-quarter 2022 financial guidance. "Despite challenging market dynamics for VASOSTRICT®, our first-quarter financial performance was in-line with our expectations with growth in our Branded Specialty Products portfolio driven by XIAFLEX® and our Generics segment driven by varenicline, the only FDA approved generic for Chantix®," said Blaise Coleman, Endo's President and Chief Executive Officer.

ENDO REPORTS FIRST-QUARTER 2022 FINANCIAL RESULTS

DUBLIN , May 5, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced the upcoming launch of a new clinical study relevant to the use of Qwo® (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in the buttocks of adult women. The design of the study will be featured during the annual Symposium for Cosmetic Advances & Laser Education (SCALE) multidisciplinary aesthetic medicine meeting, taking place in Nashville, TN, May 11-15, 2022.

News for Endo International Stock (ENDP)